<DOC>
	<DOCNO>NCT01199133</DOCNO>
	<brief_summary>The purpose study assess efficacy one dose sublingual immunotherapy ( SLIT ) administer child adolescent allergen-based tablet daily period 24 month 3 year compare placebo , reduction allergic rhinitis symptom rescue medication use .</brief_summary>
	<brief_title>Safety Efficacy Study Sublingual Immunotherapy ( SLIT ) Treat House Dust Mite Allergic Rhinitis Adolescents Children</brief_title>
	<detailed_description>After screen period , patient administer 300 IR house dust mite allergen base tablet placebo , day , period 36 month two window 8 month 6 month without treatment . The carry effect evaluate treatment free follow period 24 month . An independent Data Monitoring Committee constitute evaluate efficacy safety data end Year 1 Year 3 , post-treatment long-term efficacy data end year 4 .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Male female outpatient , age 517 year inclusive History house dust miterelated allergic rhinitis least 1 year require regular intake symptomatic treatment ( ) Sensitised D. pteronyssinus and/or D. farinae ( positive skin prick test wheal diameter great 3 mm specific IgE level ≥ 0.7 kU/L ) • Cosensitization associate clinically relevant allergic rhinitis , sinusitis , conjunctivitis asthma likely significantly change symptom patient throughout study ( mean patient symptomatic another allergen house dust mites patient expose study , i.e . notably exclude patient sensitised cat dog allergens regularly expose allergens patient sensitised aspergillus , cladosporium , alternaria patient sensitise parietaria , ragweed , mugwort , allergen endemic region</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>